Systemic chemotherapy for primary cutaneous b-cell lymphoma, leg-type: a case report

Inna A. Kamaeva; Камаева Инна Анатольевна; Irina B. Lysenko; Лысенко Ирина Борисовна; Nadezhda V. Nikolaeva; Николаева Надежда Владимировна; Elena A. Kapuza; Капуза Елена Анатольевна; Tatiana F. Pushkareva; Пушкарева Татьяна Федоровна; Tatiana O. Lapteva; Лаптева Татьяна Олеговна; Alexey V. Velichko; Величко Алексей Вячеславович

doi:10.17816/1028-9984-2020-25-6-213-218

Systemic chemotherapy for primary cutaneous b-cell lymphoma, leg-type: a case report

Authors: Kamaeva I.A.¹, Lysenko I.B.¹, Nikolaeva N.V.¹, Kapuza E.A.¹, Pushkareva T.F.¹, Lapteva T.O.¹, Velichko A.V.¹
Affiliations:
1. National Medical Research Centre for Oncology
Issue: Vol 25, No 6 (2020)
Pages: 213-218
Section: Case Reports
URL: https://rjonco.com/1028-9984/article/view/77878
DOI: https://doi.org/10.17816/1028-9984-2020-25-6-213-218
ID: 77878

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Primary cutaneous lymphomas are a group of extranodal B-cell non-Hodgkin’s lymphomas. Primary cutaneous diffuse B-large cell lymphoma, leg-type, is an extremely rare and aggressive variant of primary cutaneous lymphoma. Due to the contradictory nature, poor prognosis, and high frequency of recurrence of this disease, the treatment of patients is multidisciplinary, based on an accurate histological and immunohistochemical classification as well as risk factor assessment. In this report, we present a clinical case of primary cutaneous B-large cell skin lymphoma, leg-type, with a positive response to chemotherapy.

Clinical case. A clinical observation of chemotherapy of a patient with primary B-large cell skin lymphoma, leg-type, is presented. The patient underwent 6 R-CHOP chemotherapy courses and achieved an uncertain complete disease remission.

Conclusion. The results obtained confirm the limited literature data on the need for timely administration of systemic chemotherapy in the management of this pathology.

Keywords

primary cutaneоus b-cell lymphoma, clinical case, systemic chemotherapy

Full Text

About the authors

Inna A. Kamaeva

National Medical Research Centre for Oncology

Author for correspondence.
Email: inkamaeva@yandex.ru
ORCID iD: 0000-0003-3001-0675

младший научный сотрудник отдела лекарственного лечения опухолей

Russian Federation, Rostov-on-Don

References

Tadiotto Cicogna G, Ferranti M, Lazzarotto A, Alaibac M. Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas. Front Oncol. 2019;9:1238. doi: 10.3389/fonc.2019.01238
Guskova NK, Selyutina ON, Novikova IA, et al. Morphological and immunofenotypic features of the monoclonal population of B-lymphocytes in chronic lymphocytic leukemia. South Russian Journal of Cancer. 2020;1(3):27-35. (In Russ). doi: 10.37748/2687-0533-2020-1-3-3
Penskaya EA, Babaeva FE, Kravchenko SK, et al. Primary cutaneous diffuse b-large cell lymphoma, the leg type, with atypical clinical picture and indolent cours. Russian Journal Of Hematology And Transfusiology. 2015;60(4):41-44. (In Russ).
Vitiello P, Sica A, Ronchi A, et al. Primary Cutaneous B-Cell Lymphomas: An Update. Front Oncol. 2020;10:651. doi: 10.3389/fonc.2020.00651
Mitteldorf C, Berisha A, Pfaltz MC, et al. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. Am J Surg Pathol. 2017;41(7):998-1004. doi: 10.1097/PAS.0000000000000851
Gulia A, Saggini A, Wiesner T, et al. Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment. J Am Acad Dermatol. 2011;65(5):991-1000. doi: 10.1016/j.jaad.2010.06.059
Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535-541. doi: 10.1001/jamadermatol.2013.7452
Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671-3678. doi: 10.1182/blood-2004-04-1594
Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133
Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144-1150. doi: 10.1001/archderm.143.9.1144
Ducharme O, Beylot-Barry M, Pham-Ledard A, et al. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. J Invest Dermatol. 2019;139(11):2334-2342 e2338. doi: 10.1016/j.jid.2019.05.008
Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926. doi: 10.1038/nm.3884
Kuo H-P, Hsieh S, Schweighofer KJ, et al. The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma. Blood. 2015;126(23):699-699. doi: 10.1182/blood.V126.23.699.699
Fink-Puches R, Wolf IH, Zalaudek I, et al. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847-853. doi: 10.1016/j.jaad.2005.01.093
Arkhipova OE, Chernogubova EA, Tarasov VA, et al. The level of oncological diseases as an indicator of medical-ecological safety of territories (the rostov region being exemplified). Vestnik Yuzhnogo nauchnogo tsentra RAN. 2013;9(3):7-14. (In Russ).